Deaths Force End to Celgene Trial to Expand Top Cancer Drug

Celgene Corp. stopped a trial of Revlimid, its biggest-selling drug, after more people died using the product than those who were given a competing therapy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.